TRTP-40X

TRTP-40X is an experimental therapeutic candidate developed by Cell In Cells, a South Korean biotechnology company. It is part of the company's Tissue-Regenerative Therapeutic Platform (TRTP), which utilizes a proprietary "cell-in-cell" (CiC) technology. This platform focuses on the delivery of functional cellular components or organelles, such as mitochondria, into host cells to restore biological function and promote tissue repair. While specific clinical details for TRTP-40X are limited, the 400-series within the Cell In Cells pipeline (which includes TRTP-401) is primarily directed toward the treatment of erectile dysfunction (ED). The therapy aims to regenerate damaged vascular or neural tissues to restore physiological function, representing a novel approach in regenerative medicine that moves beyond traditional cell injections to intracellular delivery of therapeutic cargo.